Explore

Trendline Trendline
Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges

Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges

Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges
Trendline Trendline
Biogen Advances Tau Alzheimer's Therapy to Phase 3 Amid Cautious Optimism

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Amid Cautious Optimism

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Amid Cautious Optimism
Trendline Trendline
Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback
Trendline Trendline
Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback
Trendline Trendline
Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges
Trendline Trendline
PepGen Reports Financial Results and Advances in Neuromuscular Therapy Trials

PepGen Reports Financial Results and Advances in Neuromuscular Therapy Trials

PepGen Reports Financial Results and Advances in Neuromuscular Therapy Trials
Trendline Trendline
Palatin Technologies Reports Q3 2026 Financial Results and Business Update

Palatin Technologies Reports Q3 2026 Financial Results and Business Update

Palatin Technologies Reports Q3 2026 Financial Results and Business Update
Trendline Trendline
Sarepta Therapeutics to Discuss Genetic Medicine at RBC Healthcare Conference

Sarepta Therapeutics to Discuss Genetic Medicine at RBC Healthcare Conference

Sarepta Therapeutics to Discuss Genetic Medicine at RBC Healthcare Conference
Trendline Trendline
AstraZeneca's Hypoparathyroidism Drug Faces Efficacy Questions Amid Rivalry

AstraZeneca's Hypoparathyroidism Drug Faces Efficacy Questions Amid Rivalry

AstraZeneca's Hypoparathyroidism Drug Faces Efficacy Questions Amid Rivalry
Trendline Trendline
Angelini Pharma Enters U.S. Market with $4.1 Billion Acquisition

Angelini Pharma Enters U.S. Market with $4.1 Billion Acquisition

Angelini Pharma Enters U.S. Market with $4.1 Billion Acquisition
Trendline Trendline
MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5M

MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5M

MacroGenics to Sell GMP Manufacturing Operations to Bora for $122.5M
Trendline Trendline
Enanta Pharmaceuticals Reports Q2 Financial Results and Advances Clinical Programs

Enanta Pharmaceuticals Reports Q2 Financial Results and Advances Clinical Programs

Enanta Pharmaceuticals Reports Q2 Financial Results and Advances Clinical Programs